Jenburkt Pharmaceuticals Ratios

Jenburkt Pharmaceuticals Ltd Ratios

The Jenburkt Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Jenburkt Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Jenburkt Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Jenburkt Pharmaceuticals Ltd (NSE: , BSE: 524731) is currently trading at ₹1004, with a market capitalization of ₹4.43B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Jenburkt Pharmaceuticals Ltd remains a key stock for fundamental analysis using Jenburkt Pharmaceuticals Ltd Ratios.

Jenburkt Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Jenburkt Pharmaceuticals Ltd P/E ratio currently stands at 13.93, making it one of the most tracked metrics in Jenburkt Pharmaceuticals Ltd Ratios.

Historically, the Jenburkt Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 13.93
• 2023: 11.71
• 2022: 11.94
• 2021: 11.66
• 2020: 11.08

The rising Jenburkt Pharmaceuticals Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Jenburkt Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.60.

Historical P/B trend:

• 2024: 2.60
• 2023: 2.10
• 2022: 2.50
• 2021: 2.22

Jenburkt Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Jenburkt Pharmaceuticals Ltd P/S ratio currently stands at 2.94, an important part of Jenburkt Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.94
• 2023: 2.14
• 2022: 2.15
• 2021: 2.10

The rising Jenburkt Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

Jenburkt Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Jenburkt Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 14.36.

Historical Jenburkt Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 14.36
• 2023: 19.21
• 2022: 13.70
• 2021: 21.62
• 2020: 8.11

The declining Jenburkt Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Jenburkt Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Jenburkt Pharmaceuticals Ltd EV currently stands at ₹4.27B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 4.27B
• 2023: 2.3B
• 2022: 2.47B
• 2021: 2.2B

Jenburkt Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Jenburkt Pharmaceuticals Ltd EV/EBITDA ratio is currently 10.35, a key metric in Jenburkt Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 10.35
• 2023: 6.82
• 2022: 7.99
• 2021: 8.05

Higher Jenburkt Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

Jenburkt Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Jenburkt Pharmaceuticals Ltd D/E ratio is currently 0.02, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.02
• 2023: 0
• 2022: 0.02
• 2021: 0.06

Jenburkt Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Jenburkt Pharmaceuticals Ltd ROE currently stands at 20.25%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 20.25
• 2023: 19.43
• 2022: 20.53
• 2021: 20.66

Jenburkt Pharmaceuticals Ltd demonstrates strong profitability and efficient capital utilization.

Jenburkt Pharmaceuticals Ltd Ratios Analysis Summary

The Jenburkt Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Jenburkt Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Jenburkt Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.